Pop quiz: What disease killed John Keats at age 26, John Harvard at 30, Simon Bolivar at 47, Puccini's Mimi right after "Sono Andati?" - and now kills 4,400 people every day, most in the prime of their lives? Answer: TB, an ancient scourge whose current manifestations demonstrate both the highs and the lows of global public health.
CGD Policy Blogs
The vaccine industry is looking healthier and happier than it has in years, according to The Economist, thanks to the combination of new science, new money and new recognition of the value of prevention. The advances in adjuvants - ingredients in vaccines that make the antigens go further and work better - and new ways to deliver vaccines without needles, such as nasal sprays mean that genuine innovations are hitting the market.
Perhaps as a build up to the Global Fund's second replenishment process, which is in full swing in Oslo this week, there has been quite a buzz about new money for the Global Fund moving its assets to over 10 billion dollars. Two weeks ago, the Global Fund announced that with its newly pledged historic contribution of US$724 million for FY07, the United States contributions and commitments now total at US$3 billion, which constitutes 29% of all paid in contributions and firm pledges. Japan has also stepped up to the plate with a recent contribution:
In the end, will the world-wide eradication of polio go down in the "grand success" or "dismal failure" side of the global health ledger book? That was the basic question faced by World Health Organization Director-General Margaret Chan and a host of polio experts at a conference held this week to review the international polio program's progress and problems.